Catherine Heath Selected Research

Neoplasms (Cancer)

2/2014

Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Catherine Heath Research Topics

Disease

5	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 11/2012
2	Neoplasm Metastasis (Metastasis) 01/2021 - 10/2020
1	Urethral Stricture 10/2020
1	Urinary Incontinence 10/2020
1	Neoplasms (Cancer) 02/2014
1	Water Intoxication 11/2013
1	Cystitis 11/2013

Drug/Important Bio-Agent (IBA)

1	AndrogensIBA 01/2021
1	Androgen Receptors (Androgen Receptor)IBA 01/2021
1	Hormones (Hormone)IBA 01/2021
1	Dihydrotachysterol (AT 10)IBA 10/2020
1	nintedanibIBA 02/2014
1	AfatinibIBA 02/2014
1	SodiumIBA 11/2013
1	Mesna (Coenzyme M)FDA LinkGeneric 11/2013
1	DNA (Deoxyribonucleic Acid)IBA 11/2012
1	VaccinesIBA 11/2012
1	A-Form DNA (A-DNA)IBA 11/2012

Therapy/Procedure

3	Radiotherapy 01/2021 - 01/2020
1	Therapeutics 01/2021
1	Drug Therapy (Chemotherapy) 01/2021
1	Prostatectomy (Retropubic Prostatectomy) 10/2020
1	Adjuvant Radiotherapy 10/2020
1	Brachytherapy 01/2020
1	Castration 02/2014